Dayan-Daycoval Family Hematology and Oncology Center, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
Eur J Cancer Care (Engl). 2019 Sep;28(5):e13122. doi: 10.1111/ecc.13122. Epub 2019 Jun 30.
To analyse clinical outcomes comparing two age groups of patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT), and to identify risk factors associated with older patients' mortality.
In this retrospective study, the medical charts of all consecutive patients admitted in one hospital for allo-HSCT were reviewed. Overall survival (OS) and other outcomes were compared between patients aged up to 55 years (YG) and older than 55 (EG).
From January 2007 to August 2014, 111 adult patients were admitted for allo-HSCT and were included 75 in the YG and 36 in the EG group. The OS rate at D+ 100 was 84% for YG individuals in contrast to 75% in the EG (p = 0.01), and 71% vs. 50% at one year after HSCT (p = 0.01) respectively. Therapy-related mortality (TRM) rates for the YG and EG were, respectively, 14% vs. 17% (p = 0.04) at D+ 100 and 17% vs. 32% (p = 0.04) at one year. Haploidentical donor type and active disease status significantly increased mortality risk in the EG (hazard ratio 2.42; p = 0.018; and 2.04; p = 0.033).
YG and EG have similar TRM rates early after allo-HSCT, but the elderly had higher TRM during the critical period from 100 days to one year.
分析比较两组接受异基因造血干细胞移植（allo-HSCT）的患者的临床结果，并确定与老年患者死亡相关的危险因素。
在这项回顾性研究中，对一家医院接受 allo-HSCT 的所有连续患者的病历进行了回顾。在年龄不超过 55 岁（YG）和大于 55 岁（EG）的患者之间，比较了总生存率（OS）和其他结果。
从 2007 年 1 月至 2014 年 8 月，共有 111 名成人患者接受 allo-HSCT 治疗，其中 75 名患者纳入 YG 组，36 名患者纳入 EG 组。YG 患者在 D+100 时的 OS 率为 84%，而 EG 组为 75%（p=0.01），HSCT 后 1 年时分别为 71%和 50%（p=0.01）。YG 和 EG 的治疗相关死亡率（TRM）分别为 D+100 时的 14%和 17%（p=0.04）和 1 年时的 17%和 32%（p=0.04）。半相合供体类型和活动性疾病状态显著增加了 EG 中的死亡风险（危险比 2.42；p=0.018；和 2.04；p=0.033）。
YG 和 EG 在 allo-HSCT 后早期的 TRM 率相似，但老年人在从 100 天到 1 年的关键时期的 TRM 更高。
Zotero 插件